Endologix Inc /de/ (ELGX) Files Form 4 Insider Selling : Joseph A. Dejohn Sells 957 Shares

Endologix Inc /de/ (ELGX): Joseph A. Dejohn , General Manager, Asia & Pac of Endologix Inc /de/ sold 957 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 2, 2016 to the Securities and Exchange Commission. The shares were sold at $12.55 per share for a total value of $12,010.35 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Jose A. Lima (VP-Quality) sold 957 shares at $12.55 per share price.On Jun 2, 2016, John D Mcdermott (Chief Executive Officer) sold 6,116 shares at $12.55 per share price.Also, On Jun 2, 2016, Amanda L. Depalma (VP, Global Marketing) sold 689 shares at $12.55 per share price.On May 27, 2016, James Edward Machek (VP-Research & Development) sold 6,500 shares at $12.76 per share price.

Endologix: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Endologix which led to swings in the share price. The shares opened for trading at $12.55 and hit $12.98 on the upside , eventually ending the session at $12.69, with a gain of 0.16% or 0.02 points. The heightened volatility saw the trading volume jump to 25,59,582 shares. The 52-week high of the share price is $17.02 and the company has a market cap of $1,038 M . The 52-week low of the share price is at $6.505.

Endologix Money Flow Index Chart

Company has been under the radar of several Street Analysts.Endologix is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 15 from a previous price target of $11 .The Rating was issued on May 10, 2016.Endologix is Resumed by JP Morgan to Overweight. The Rating was issued on Apr 4, 2016.

Endologix Inc. is engaged in developing manufacturing marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS) its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Company’s EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Leave a Reply

Endologix - Is it time to Sell?

Top Brokerage Firms are advising their investors on Endologix. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.